LONDON – Immunocore Ltd. is expecting a $100 million payment before the end of the year, after it sealed a new agreement with Roche Holding AG subsidiary Genentech Inc. around IMC-C103C, a soluble T-cell receptor (TCR) product targeted at melanoma-associated antigen A4 (Mage-A4)-expressing solid tumors.